α-ketoglutarate dehydrogenase inhibition counteracts breast cancer-associated lung metastasis by Atlante, Sandra et al.
Atlante et al. Cell Death and Disease  (2018) 9:756 
DOI 10.1038/s41419-018-0802-8 Cell Death & Disease
ART ICLE Open Ac ce s s
α-ketoglutarate dehydrogenase inhibition
counteracts breast cancer-associated
lung metastasis
Sandra Atlante1, Alessia Visintin2,3, Elisabetta Marini3, Matteo Savoia1, Chiara Dianzani3, Marta Giorgis3, Duran Sürün2,
Federica Maione2,3, Frank Schnütgen4, Antonella Farsetti5, Andreas M. Zeiher6, Massimo Bertinaria3, Enrico Giraudo2,3,
Francesco Spallotta1, Chiara Cencioni1,5 and Carlo Gaetano7
Abstract
Metastasis formation requires active energy production and is regulated at multiple levels by mitochondrial
metabolism. The hyperactive metabolism of cancer cells supports their extreme adaptability and plasticity and
facilitates resistance to common anticancer therapies. In spite the potential relevance of a metastasis metabolic control
therapy, so far, limited experience is available in this direction. Here, we evaluated the effect of the recently described
α-ketoglutarate dehydrogenase (KGDH) inhibitor, (S)-2-[(2,6-dichlorobenzoyl) amino] succinic acid (AA6), in an
orthotopic mouse model of breast cancer 4T1 and in other human breast cancer cell lines. In all conditions, AA6
altered Krebs cycle causing intracellular α-ketoglutarate (α-KG) accumulation. Consequently, the activity of the α-KG-
dependent epigenetic enzymes, including the DNA demethylation ten-eleven translocation translocation hydroxylases
(TETs), was increased. In mice, AA6 injection reduced metastasis formation and increased 5hmC levels in primary
tumours. Moreover, in vitro and in vivo treatment with AA6 determined an α-KG accumulation paralleled by an
enhanced production of nitric oxide (NO). This epigenetically remodelled metabolic environment efficiently
counteracted the initiating steps of tumour invasion inhibiting the epithelial-to-mesenchymal transition (EMT).
Mechanistically, AA6 treatment could be linked to upregulation of the NO-sensitive anti-metastatic miRNA 200 family
and down-modulation of EMT-associated transcription factor Zeb1 and its CtBP1 cofactor. This scenario led to a
decrease of the matrix metalloproteinase 3 (MMP3) and to an impairment of 4T1 aggressiveness. Overall, our data
suggest that AA6 determines an α-KG-dependent epigenetic regulation of the TET–miR200–Zeb1/CtBP1–MMP3 axis
providing an anti-metastatic effect in a mouse model of breast cancer-associated metastasis.
Introduction
For its high yearly incidence, mortality and morbidity,
breast cancer is a developing threat women face
worldwide1,2. The disease is extremely heterogeneous3
and characterised by about 20% incidence of metastasi-
zation2 mainly in bone, distant soft tissue and lung4,5.
Despite the remarkable progresses in prevention and
patient care and the scientific community effort to elu-
cidate the molecular mechanism underpinning aetiology
and development of breast cancer, the request of effective
anti-metastatic therapies remains open.
Recently, a broad interest pointed to cancer metabolism
as a promising target to develop new therapeutic
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approaches. Cancer cells are characterised by a hyperactive
metabolism and adaptability to nutrient deprivation6.
Indeed, enhanced glycolysis and/or oxidative phosphor-
ylation conferred to drugs interfering with metabolism,
including the tricarboxylic acid (TCA) cycle, promising
therapeutic potential interest, although the possibility to
elicit adverse effects needs to be carefully evaluated7–10.
TCA helps cancer to develop its adaptability in con-
sequence of the intrinsic ability to adjust metabolic fluxes
according to resource availability. Further, metabolites
produced during TCA cycle dramatically affect tumour
cell epigenetic landscape11–13. In this light, TCA cycle
relevance is validated by several specific cancer-associated
mutations occurring into the coding sequence of its
enzymes14,15. In mitochondria, the α-ketoglutarate dehy-
drogenase complex (KGDH), a key control TCA enzyme,
catalyses the oxidative decarboxylation of α-ketoglutarate
(α-KG) to succinyl-CoA exploiting the reduction of
NAD+ to NADH12,16–18. Its enzymatic activity relies on
the availability of ATP, inorganic phosphate, and NAD+
produced by glycolysis and respiratory chain controlling
the mitochondrial redox status, the metabolite flux and
many different signalling pathways, including amino acid
synthesis15,19,20. KGDH is one of the mitochondrial
enzymes most sensitive to tumour micro-environmental
changes and plays a role in the cancer adaptive metabolic
response6,21. Therefore, it is envisaged that drugs target-
ing this enzymatic complex might show interesting anti-
cancer properties.
DNA hypermethylation is an intrinsic feature of cancer
genetic landscape22–24 possibly due to ten-eleven trans-
location hydroxylase (TET) activity alterations25, which
have been associated with worse prognosis22–24. Com-
monly, in cancer, the reduced DNA demethylation
associates with specific mutations or decreased expression
of TET encoding genes, as well as with diminished α-KG
intracellular levels occurring upon its replacement with
the oncometabolite D-2-hydroxyglutarate25–28. α-KG not
only fuels energetic and anabolic routes into the mito-
chondrion but regulates also demethylation of DNA and
histones, acting as cofactor for all dioxygenases including
TETs and Lysine demethylases (KDMs)29–31. Of interest,
in a metabolically compromised environment, KGDH
inhibition increased α-KG level restoring the epi-
metabolic control on the DNA demethylation cycle32.
TET activity is particularly relevant to counteract breast
cancer progression by suppression of mechanisms asso-
ciated with the metastatic process33–35. In this context,
TET proteins de-repress the expression of tissue inhibi-
tors of metalloproteinases (TIMP 2 and 3)36 and of anti-
metastatic miRNAs, such as miR-200 family members,
demethylating their promoter regions35.
The miR-200 family consists of five members organised
in two different clusters according to chromosomal
location. Mouse chromosome 4 and 6 give rise to two
polycistronic transcripts encoding for cluster 1 (miR-200b,
miR-200a and miR-429) and cluster 2 (miR-200c and
miR-141) respectively37. In breast cancer they hinder both
epithelial-to-mesenchymal transition (EMT), the initiat-
ing step of tumour invasion, and metastatic cancer stem
cell function37–39. Most of miR-200 tumour suppressor
activity is obtained by direct targeting of the two zinc-
finger E-box binding homeobox members Zeb1 and
Zeb240–42. This family of transcription factors have been
defined as the master inducer/regulator of EMT since
they directly inhibit the cell-cell adhesion molecule E-
cadherin enhancing cell motility40–42.
Although metabolic alterations, inefficient DNA deme-
thylation and unbalanced miR-200/Zeb circuitry have
been well defined as crucial steps along metastatic pro-
gression, the presence of a functional link among all these
elements has not been thoroughly investigated yet. In the
present work, we took advantage from the properties of a
novel compound, the (S)-2-[(2,6-dichlorobenzoyl)amino]
succinic acid (AA6), able to inhibit KGDH activity, to
increase cellular α-KG levels and to restore the epi-
metabolic control upon DNA demethylation cycle32.
Here, we investigated AA6 properties as potential anti-
metastatic drug in a spontaneous lung metastasis mouse
model of breast cancer.
Results
The KGDH inhibitor AA6 prevents lung metastasis
formation in 4T1 mouse model of breast cancer
The KGDH is a TCA cycle mitochondrial enzyme
whose activity can be inhibited by (S)-2-[(2,6-dichlor-
obenzoyl)amino]succinic acid (AA6)32. In an attempt to
understand whether its inhibition might interfere with
tumour progression, we administered two doses of AA6
(12.5 mg/kg and 50mg/kg) in the 4T1 orthotopic mouse
model of breast cancer43. Interestingly, AA6 reduced the
area of lung metastasis in a dose-dependent manner
without apparently affecting growth of the primary
tumour (Fig. 1a, b, d). Further the treatment of 4T1 mice
with the dose of 50 mg/kg significantly decreased the
incidence of lung metastasis (Fig. 1c). Analysis of Ki67, a
marker of proliferating cells, and cleaved caspase 3
(Casp3), a marker of apoptosis, into the primary tumour
of untreated and AA6 treated mice revealed no difference
between the two groups. Similarly, we did not detect any
significant differences in proliferation or apoptosis in lung
metastasis (Fig. 1e–h). These data suggest that AA6 does
not directly interfere with metastasis growth but rather
could induce a delay of the metastatic process. To
investigate the anti-metastatic effect of AA6, we studied
the expression of a selected panel of genes associated with
tumour progression and metastasis. This analysis revealed
that some crucial metastatic genes were negatively
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modulated by AA6 (Fig. 2a and Supplemental table I).
Further analyses confirmed that AA6 repressed, both at
mRNA and protein level, extracellular matrix proteases
(e.g. Mmp3), cell adhesion molecules (e.g. Gpnmb), and
transcription factors associated to cancer progression
(e.g. Ctbp1) with a minor effect on cell proliferation genes
(e.g. Plaur and Src) (Fig. 2b, c). In agreement, 4T1 cells
treated with AA6 for 24 h (h) showed reduced migration
Fig. 1 (See legend on next page.)
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(Suppl. Figure 1a, b), adhesion to endothelium (Suppl.
Figure 1c) and invasion capacity (Suppl. Figure 1d). In
these experiments, the most important effects were
observed at 50 µM AA6, with a tumour cell migration
impairment/inhibition higher than 80% (Fig. 2d), in par-
allel to a significant inhibition of invasiveness (Fig. 2e). In
agreement with in vivo observations, 50 µM AA6 did not
affect survival and proliferation of 4T1 cells (Suppl. Fig-
ure 2). Interestingly, similar results were obtained in two
different human breast cell lines: the African American
human cell line CRL-2335 and the Caucasian human cell
line MDA-MB-231. CRL-2335 cell line is a recognized
model of basal-like breast carcinoma, one of the most
aggressive and deadly carcinoma sub-type characterized
by poor clinical outcomes. Of note, CRL-2335 cells are
negative for the expression of human epidermal growth
factor receptor 2 (Her2-neu), Oestrogen Receptor (ER),
and Progesterone Receptor (PR) and positive for the
expression of basal-like markers, epidermal growth factor
(EGFR), and cytokeratin 5/6 (ck 5/6)44. Conversely, the
MDA-MB-231 cell line represents one of the most com-
monly used breast cancer highly aggressive, invasive and
poorly differentiated triple-negative (Her2-neu, ER, and
PR negative) in vitro model45,46. Remarkably, AA6 down-
modulated most of the metastasis-associated genes in
both human breast cell lines (Suppl. Figure 3a, b; Suppl.
Figure 4a, b). Further, AA6 reduced serum-stimulated
chemo-attraction (Suppl. Figure 3c; Suppl. Figure 4c) and
adhesion to TNF-α-activated endothelium (Suppl. Fig-
ure 3d; Suppl. Figure 4d) without affecting viability
(Suppl. Figure 3e; Suppl. Figure 4e), survival and pro-
liferation (Suppl. Figure 3f; Suppl. Figure 4f). Hence, AA6
treatment affected tumorigenic functions of 4T1, CRL-
2335 and MDA-MB-231 cells without altering their vital
functions. Taken together these results foster AA6 as an
anti-metastatic compound active both in vivo and in vitro.
KGDH inhibition increases α-KG levels leading to DNA
demethylation and impaired cell migration
In agreement with prior data obtained from non-cancer
related dysmetabolic models32, also in breast cancer AA6
inhibited KGDH enzymatic activity (Suppl. Figure 5a)
leading to intracellular α-KG level increase (Suppl. Fig-
ure 5b). In this chemically determined α-KG-enriched
environment, we observed an increase in TET protein
expression both in vivo (Fig. 3a, b) and in vitro (Fig. 3c
and Suppl. Figure 5c) paralleled by a higher total TET
enzymatic activity (Fig. 3d). Interestingly, in 4T1 cells,
confocal analysis of TET proteins revealed that AA6
treatment rescued the predominant cancer-associated
extra-nuclear localisation of these proteins47,48 (Fig. 3c).
TET1 and TET3 re-localisation into the nucleus was
further confirmed by the biochemical analysis of nucleus/
cytoplasm fractions (Suppl. Figure 5d). Remarkably, the
intra-nuclear TET re-localisation was paralleled by a
global reduction of DNA 5-methyl cytosine (5mC) and a
relative increase in the content of 5-hydroxymethyl
cytosine (5hmC) both in vivo and in vitro (Fig. 3e, f).
Similar results were observed in CRL-2335 cells and
MDA-MB-231 cells upon AA6 treatment (Suppl. Fig-
ure 3g; Suppl. Figure 4g). In order to investigate AA6
molecular mechanism, KGDH expression was knocked-
down (KD) in 4T1 cells by CRISPR/Cas9 technology
(Fig. 4a). KGDH expression KD significantly affected its
enzymatic activity (Fig. 4b) leading to a relative accumu-
lation of intracellular α-KG (Fig. 4c). Of note, CRISPR/
Cas9 vector 2 was more efficient than vector 1 eliciting a
higher increase of α-KG levels. AA6 effect on total TET
enzymatic activity as well as on 5mC and 5hmC was
reproduced in 4T1 KGDH KD cells (Fig. 4d–f). Remark-
ably, the partial inhibition of KGDH impaired 4T1 cell
migration (Fig. 4g) without altering cell viability and
proliferation (Suppl. Figure 6a-c). All these evidences
suggested that the KGDH complex might function as a
key metabolic enzyme during metastatic progression and
that AA6 counteracts this process.
AA6 stimulates the endogenous synthesis of nitric oxide
Taking under consideration the impact that α-KG
fluctuations might have on different intracellular path-
ways, we evaluated the involvement of additional
mechanisms in the anti-metastatic response to AA6.
(see figure on previous page)
Fig. 1 AA6 prevents 4T1 cell lung metastasis formation. a Hematoxylin and eosin staining: arrows represent lung metastasis reduction after
3 weeks of treatment of 4T1 orthotopic mouse model of breast cancer with AA6 (12.5 mg/kg n= 10; 50 mg/kg n= 5), compared to controls; n= 10.
Scale bar 50 μm. b–d The graph shows the measured metastasis area in AA6 treated mice (12.5–50 mg/kg; grey bars) compared to controls (black
bars) (b) and the percentage of metastasis incidence analysed by Mantel-Cox Test (*p= 0.0082) (c); no difference was observed in the primary -
tumour volume (d). e, f Representative confocal images (left panels) and relative densitometry (right panels) showing cell proliferation (Ki67) (e) and
apoptosis (CASP3) (f) in AA6 treated mice primary tumour (12.5–50 mg/kg; grey bars) compared to controls (black bars). Samples were probed by an
anti-Ki67 antibody (green; monoclonal), anti-CASP3 (green; monoclonal) and counterstained by DAPI (blue). Scale bar 50 μm; control n= 10; 12.5 mg/kg
n= 10; 50mg/kg n= 5. g, h Representative immunohistochemistry images (left panels) and relative quantification (right panels) showing cell
proliferation (Ki67) (g) and apoptosis (CASP-3) (h) in AA6 treated mice primary tumour (grey bars) compared to controls (black bars). Samples were
probed by an anti-Ki67 antibody (monoclonal), anti-CASP3 (monoclonal) and counterstained by hematoxylin. Scale bar 50 μm; control n= 10;
12.5 mg/kg n= 10; 50 mg/kg n= 5. Data are presented as mean ± SE; *p < 0.0332, **p < 0.0021, ***p < 0.0002 vs controls. Data were analysed by non-
parametric Mann–Whitney test
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Fig. 2 (See legend on next page.)
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α-KG is a relevant precursor of ornithine, a non-
proteinogenic amino acid, which leads to L-arginine
(L-Arg) synthesis through the urea cycle. As a substrate,
L-Arg contributes to NO synthases (NOS) activation
fostering the endogenous production of NO49. Recently,
NO-donors have been proposed as promising therapeutic
options for breast, liver and skin cancers50 and, in this
perspective, we reasoned that the anti-metastatic role of
AA6 might be not only associated to its modulation of
mitochondrial metabolism and TET activation but also to
an effect on endogenous NO synthesis. To explore this
possibility, we investigated AA6 effect on the α-KG/L-
Arg/NO axis. A slight but significant increase of L-Arg
content was observed both in vivo (Fig. 5a) and in vitro
(Fig. 5b) either upon AA6 treatment or after KGDH KD
(Suppl. Figure 6d). Interestingly, an increase in the total
amount of nitrates and nitrites, conceivably by-products
of NO synthesis, was detected in the tumorigenic tissue of
AA6 treated mice (Fig. 5c). In agreement with this
observation, after 16 h of AA6 in vitro treatment,
increased NO levels were detected in 4T1 cells as deter-
mined by the FACS analysis of signals generated by the
fluorescent indicator 4,5-diaminofluorescein-2 diacetate
(DAF-2DA; Fig. 5d). The ability of AA6 to induce endo-
genous NO synthesis was verified by the addition of the
NO scavenger 2-Phenyl-4,4,5,5-tetramethylimidazoline-
1-oxyl 3-oxide (PTIO) to 4T1 cells treated with AA6. As
expected, PTIO significantly reduced NO levels (Fig. 5e).
Consistently, similar increase in NO production was
observed in 4T1 KGDH KD cells (Suppl. Figure 6e).
Taken together these data suggest that AA6 has the
unprecedented property to activate NO synthesis possibly
acting via enhancement of the metabolic/biosynthetic α-
KG/L-Arg/NO axis.
AA6 impairs the EMT process through activation of miR-
200 family and Zeb1 down modulation
It has been recently reported that miR-200 family
expression is controlled by endogenous NO allowing for
the mesendodermal differentiation of mouse embryonic
stem cells51,52. miR-200 family is usually down-modulated
during tumour progression. This phenomenon is
believed to prevent the miR-200-dependent inhibition of:
(i) EMT; (ii) cancer stem cell self-renewal/differentiation;
(iii) chemoresistance37–39. Intriguingly, as miR-200 family
presents CpG-rich sequences, a down-modulation
mechanism used by cancer is the hypermethylation at
the regulatory regions of both clusters to favour tumour
formation and increase cell invasion ability25,27,35. To
understand whether AA6 treatment might have an effect
on the tumour suppressor miR-200 family we investigated
DNA methylation at miR-200 gene loci and their response
to endogenous NO production in 4T1 cells. Methylation
analysis revealed that AA6 significantly reduced 5mC
levels in two different regulatory regions of both miR-200
cluster 1 and 2 (Fig. 6a). The methylation reduction
allowed miR-200 family transcription in vivo (Fig. 6b, c)
and in vitro (Fig. 6d) as shown by pri-miR and miR parallel
expression analysis. AA6 ability to positively regulate NO
production and miR-200 family expression prompted us to
investigate other players of the EMT process, such as the
transcriptional repressor Zeb1, a direct target of miR-200s.
Zeb1, a zinc-finger homeodomain transcription factor,
actively facilitates EMT by transcriptional inhibition of
the cell–cell adhesion molecule E-cadherin, a hallmark of
the initiating step of cancer metastasis. AA6 administra-
tion in mice injected with 4T1 cells into the mammary
gland significantly reduced Zeb1 protein level (Fig. 6e).
The same result was obtained in 4T1, CRL-2335 and
MDA-MB-231 cells treated with AA6 and in KGDH KD
cells (Fig. 6g; Suppl. Figure 3h; Suppl. Figure 4h; and
Suppl. Figure 7b). Specifically, in 4T1 cells Zeb1 expres-
sion was reduced both at mRNA and protein level (Fig. 6f, g)
in response to miR-200 family increase as demonstrated
by experiments in which miR-200c was KD by validated
LNA oligos (Fig. 6h). Moreover, Zeb1 is known to
bind CtBP1 corepressor53,54, a transcriptional factor
associated to cancer progression present among the most
modulated genes in the tumour metastasis PCR array
analysis reported here and whose down-modulation was
(see figure on previous page)
Fig. 2 AA6 administration decreases metastasis-associated transcripts and interferes with 4T1 cells migration. a Heatmap showing the 53
most differentially regulated genes in tumour mass derived from AA6 injected mice (50 mg/kg), or untreated mice; n= 3 each group. Yellow and
blue represent over- and under-expressed genes, respectively. b mRNA expression analysis of Matrix metallopeptidase 3 (Mmp3), Glycoprotein
transmembrane non-metastatic B (Gpnmb), C-terminal binding protein 1 (Ctbp1), Plasminogen activator, urokinase receptor (Plaur) and Rous
sarcoma oncogene (Src) genes in AA6 injected mice (50 mg/kg; grey bars) and control mice (black bars); n= 5. c Representative western blot (upper
panels) and relative densitometry (lower panel) of MMP3, GPNMB, CtBP1 and SRC protein levels in AA6 (50 mg/kg; grey bars) treated mice compared
to controls (black bars). GRB2 and GAPDH were used as loading controls; n= 5 each group. d Representative phase contrast microscopy images
(upper panel) depicting 4T1 cells motility after 24 h treatment with AA6 (50 µM) or vehicle alone; the graph (lower panel) shows the percentage of
closure in 4T1 cells after 24 h treatment with AA6 (50 µM; grey bar) or vehicle (black bar). Scale bar 100 μm; n= 5 each group. e Representative
pictures (upper panel) showing 4T1 cell invasiveness after AA6 (50 µM) treatment versus vehicle; the graphs (lower panel) represent migrated cells
counted after 24 h treatment with AA6 (50 µM; grey bar) or vehicle alone (black bar). Scale bar 50 μm; n= 3. Data are presented as mean ± SE;
*p < 0.05, **p < 0.005, ***p < 0.0005 vs controls. Data were analysed by two-way ANOVA and non-parametric two-tailed paired Student’s t-test
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Fig. 3 KGDH inhibition increases TET expression and modulates 5mC/5hmC global levels both in vivo and in vitro. a Ten-eleven
translocation hydroxylases (Tet) -1, 2, 3 mRNA expression levels in AA6 injected mice (50 mg/kg; grey bars) and control mice (black bars); n= 5.
b Representative western blot (left panel) and relative densitometry (right panel; n= 4) of TET1, 2, 3 in AA6 (50 mg/kg; grey bars) treated
mice compared to controls (black bars). α-tubulin and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were used as a loading controls.
c Representative confocal images depicting the intracellular content of TET1, 2, 3 enzymes in 4T1 cells treated with AA6 (50 µM) or vehicle alone. Cells
were probed by an anti-TET1 antibody (red; monoclonal), TET2 (green; polyclonal), TET3 (green; polyclonal) and counterstained by DAPI (blue). Scale
bar 25 μm; n= 3. d TET activity quantification performed in 4T1 cells treated with AA6 (50 µM; grey bar) for 48 h indicated as percentage versus
vehicle-treated cells (black bar); n= 3. e Quantification of 5mC (left panel) and 5hmC (right panel) global levels in 4T1-injected mice after AA6
administration (50 mg/kg; grey bars) compared to untreated mice (black bars); n= 5 each group. f Quantification of 5mC (left panel) and 5hmC (right
panel) global levels in 4T1 cells exposed to AA6 (50 µM; grey bars) for 48 h indicated as fold-change versus vehicle-treated cells (black bars); n= 3
each group. Data are presented as mean ± SE; *p < 0.05 vs controls. Data were analysed by two-way ANOVA and non-parametric two-tailed paired
Student’s t-test
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Fig. 4 CRISPR/Cas9 KGDH inactivation increases α-KG levels, TET activity and global 5hmC and interferes with 4T1 cell line biological
properties. a Representative WB (left panel) and relative densitometry (right panel) of KGDH protein levels in 4T1 cells after CRISPR/Cas9 inactivation
of KGDH (LCv2_KGDH_1 and LCv2_KGDH_2) compared to control vector (LCv2_NTC). α-tubulin was used as a loading control; n= 5. b KGDH activity
and c α-KG level quantification of LCv2_NTC- (black bars), LCv2_KGDH_1- (dark grey bars) and LCv2_KGDH_2- (light grey bars) 4T1 cells; n= 3 each
group. d TET activity quantification performed in LCv2_KGDH_1- (dark grey bar) and LCv2_KGDH_2- (light grey bar) 4T1 cells compared to LCv2_NTC
(black bar); n= 3. e Global 5mC and f 5hmC levels in 4T1 cells after CRISPR/Cas9 inactivation of KGDH (LCv2_KGDH_1 and LCv2_KGDH_2; grey bars)
compared to control vector (LCv2_NTC; black bars); n= 3 each group. g Representative phase contrast microscopy images (left panel) and relative
percentage of closure measurements (right panel) showing 4T1 cells motility after CRISPR/Cas9 inactivation of KGDH (LCv2_KGDH_1; medium grey
bar and LCv2_KGDH_2; light grey bar) compared to control vector (LCv2_NTC; black bar) in the presence or absence of AA6 (50 µM; dark grey bars).
Scale bar 100 μm; n= 3 each condition. Data are presented as means ± SE; *p < 0.05, **p < 0.005, ***p < 0.0005 vs controls. Data were analysed by
non-parametric two-tailed paired Student’s t-test
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validated by qRT-PCR and western blot (Fig. 2a–c).
CtBP1 expression down-modulation by AA6 treatment
was further confirmed in vitro (Suppl. Figure 7d).
Relevantly, the tumour metastasis PCR array analysis
pointed out MMP3 as one of the most down-regulated
targets of AA6 (Fig. 2a–c). MMP3 is a matrix-metallo
protease contributing to initiate the metastatic spread in
various tumours55. Recently, Sun et al. demonstrated that
MMP3 is an indirect target of miR-200 family/Zeb1 axis56
acting on the downregulation of MMP3 via Zeb1/phos-
phorylated-SMAD3 interaction56. In our experiments, the
anti-metastatic potential of AA6 was further confirmed
in vivo and in vitro by the inhibition of MMP3 expression
both at mRNA and protein level (Fig. 2b, c; Suppl. Fig-
ure 7c, d). Similar effects were observed in 4T1 KGDH
KD cells (Suppl. Figure 7a-b). Moreover, to understand
whether Zeb1 inhibition was important for AA6 anti-
metastatic effect, 4T1 cells were transfected either with an
empty vector (pCMV6_EV) or with a plasmid carrying
Zeb1 (pCMV6_Zeb1). As expected, transfected cells
expressed significantly higher levels of Zeb1 compared to
controls (Fig. 7a). The forced expression of Zeb1 was
Fig. 5 AA6 increases nitric oxide-release in 4T1 cells. a L-Arginine levels in 4T1-injected mice after AA6 administration (50 mg/kg; grey bar)
compared to untreated mice (black bar); n= 3. b L-Arginine levels in 4T1 cells after 16 h of treatment with AA6 (50 µM; grey bar) or vehicle alone
(black bar); n= 3. c Nitrate and nitrite quantification in 4T1-injected mice after AA6 administration (50 mg/kg; grey bar) compared to untreated mice
(black bar); n= 3. d Representative dot plot (left panel) and relative densitometry (right panel) showing NO-release evaluation by FACS analysis of
DAF-2DA-stained 4T1 cells, after 6, 16, and 24 h of treatment with AA6 (50 µM; grey bars), expressed as fold change to vehicle-treated cells (black bar);
the gated cell populations (blue, P5) indicate DAF-2T-positive cells for each condition, negative controls were in absence of DAF-2D; n= 3 each
group. e Representative dot plot (left panel) and relative densitometry (right panel) showing NO-release evaluation by FACS analysis of DAF-2 DA
stained 4T1 cells after 16 h of treatment with vehicle only (black bar), AA6 (50 µM; light grey bar) and AA6 (50 µM)+ PTIO (100 µM; dark grey bar);
n= 4 each condition. Data are presented as mean ± SE; *p < 0.05, ***p < 0.0005 vs controls. Data were analysed by one-way ANOVA and non-
parametric two-tailed paired Student’s t-test
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paralleled by an increase in CtBP1 and MMP3 protein
expression (Fig. 7a). In this condition, Zeb1 restored the
migratory ability of the cells regardless the presence of
AA6 (Fig. 7b). Further experiments performed in the
presence of the NO scavenger PTIO indicated that AA6-
dependent increase of NO played an important role in the
miR-200 family response (Fig. 7c) determining Zeb1
down-modulation (Fig. 7d) and motility reduction of
4T1 cells (Fig. 7e). Similar results were obtained in 4T1
KGDH KD cells (Fig. 7f). Taken together these results
Fig. 6 AA6 prevents metastasization targeting the TET–miR200–Zeb1/CtBP1–MMP3 axis. a Relative enrichment of 5mC in selected CCpGG
sites of miR-200 family promoter regions for cluster 1 (left panel) and cluster 2 (right panel) in 4T1-injected mice DNA treated with AA6 (50 mg/kg;
grey bars) versus control mice DNA (black bars); n= 5. b Pri-miR-200 cluster 1 (left panel) and cluster 2 (right panel) level of AA6 (50 mg/kg; grey bars)
treated 4T1-injected mice expressed as fold-induction compared to untreated mice (black bars); n= 3. c Cluster 1 (miR-200b, miR-200a and miR-429;
left panel) and cluster 2 (miR-200c and miR-141; right panel) expression in 4T1-injected mice treated with AA6 (50 mg/kg; grey bars), the graph
represents average fold changes versus controls (black bars); n= 4. d Cluster 1 (miR-200b, miR-200a and miR-429; left panel) and cluster 2 (miR-200c
and miR-141; right panel) expression in 4T1 cells treated with AA6 (50 µM; grey bars) for 6, 16, and 24 h, bar graphs represent average fold changes
versus vehicle-treated cells (black bars); n= 4. e Representative WB (left panel) and relative densitometry (right panel; n= 5) of ZEB1 protein level in
AA6 (50 mg/kg; grey bar) treated mice compared to controls (black bar). GAPDH and Red Ponceau were used as loading controls. f, g Zeb1 mRNA
expression levels (f) and representative western blotting analysis of ZEB1 protein expression (g) in 4T1 cells exposed to AA6 (50 µM; grey bars) for 48 h
indicated as fold-change versus vehicle-treated cells (black bars); the right panel shows the relative densitometry as fold-change versus vehicle.
α-tubulin was used as loading control; n= 4. h Representative WB (left panel) and relative densitometry (right panel) of ZEB1 protein expression level
in AA6 treated 4T1 cells compared to vehicle-treated cells after transfection either with scramble-LNA (vehicle: black bar; AA6 50 µM: light grey bar) or
anti-miR-200c-LNA (vehicle: dark grey bar; AA6 50 µM: medium grey bar). α-tubulin was used as loading control; n= 4. Data are presented as mean ±
SE; *p < 0.05, **p < 0.005 vs controls. Data were analysed by one and two-way ANOVA and non-parametric two-tailed paired Student’s t-test
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Fig. 7 (See legend on next page.)
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suggest that, further to TET activation, miR-200 induc-
tion, possibly associated with endogenous NO synthesis
enhancement, leads to the inhibition of the master EMT
inducer Zeb1 conceivably contributing to the anti-
metastatic effect of AA6.
Discussion
The recent evidence that metabolic alteration might
contribute to transformation and tumour progression
raised interest in anticancer approaches aimed at control-
ling transformation and metastasization processes6,12,15.
Exciting results have been obtained in preclinical cancer
models where different metabolic pathways have been
targeted by selective drugs7–10. Specifically, pathways
involved in nutrient supplying, energy production and
molecular biosynthesis were chosen as novel pharmacolo-
gical targets7–10. Little is known, however, about the
potential anticancer effect of drugs able to increase the
intracellular level of specific metabolites and their impact
on metastasization. In the present study we evaluated
whether the novel epi-metabolic drug AA6 might chal-
lenge lung metastasis formation in the 4T1 orthotopic
mouse model of breast cancer.
4T1 tumour cell line, a recognized model for breast
cancer studies originally isolated by Miller and collea-
gues57,58 was exploited. 4T1 cell injection into the mam-
mary gland of BALB/c mice gives rise to a mammary
carcinoma with characteristics resembling the human
one. After injection, primary tumour grows into the
mammary gland and spontaneously develops lung
metastasis even after surgical removal of the original
tumour, a situation resembling that occurring in real
clinical situations43,59.
Taking advantage from this model, we found that
ketoglutarate dehydrogenase inhibition, following AA6
treatment, reduced the initiating steps of tumour invasion.
Indeed, the master regulators of EMT, miR-200 family
and Zeb1 transcription factor37–42, resulted differentially
regulated by KGDH inhibition. Specifically, AA6 induced
miR-200 expression and consequently repressed Zeb1
levels. Surprisingly, AA6 not only acted on α-KG levels,
but it was also able to increase the expression and nuclear
localisation of TET proteins, a fundamental step toward
re-activation of DNA demethylation. Indeed, cancer
genetic landscape is characterized by hypermethylation
paralleled by TET activity alterations22–24. Different cau-
ses have been accounted for these alterations including
(i) specific mutations, (ii) molecular mechanisms leading
to reduced expression of TET proteins25–28, (iii) deloca-
lisation out of the nucleus47,48. In breast cancer, TET
activity counteracts tumour progression suppressing
metastasis development:33–35 it de-represses the expres-
sion of tissue metalloproteinase inhibitors36 and of anti-
metastatic miRNAs, demethylating their promoter
regions35. In this scenario, the AA6 dependent boost of
TET activity, consequent to increased expression and
nuclear re-localisation, suggests AA6 as a promising tool
to counteract metastasis formation in experimental breast
cancer. The inversion between 5mC and 5hmC DNA
global levels observed following AA6 treatment, in fact,
might specifically hit TET promoter regions activating
their transcription. These observations were in line with
the recent description that AA6 restored the epi-
metabolic control on the DNA demethylation cycle in a
metabolically compromised intracellular environment32.
KGDH role as AA6 target, was further confirmed by
experiments performed in two human breast cancer cell
lines (CRL-2335 and MDA-MB-231) and in 4T1 cells in
which KGDH was reduced by CRISPR/Cas9 technology.
These results pointed out how α-KG fluctuations might
interfere with gene transcription regulation. Moreover, the
evidence of this communication strengthens the concept
of a close interaction between metabolic pathways and
epigenetic mechanisms and shed light on the tight coop-
eration between the cell metabolite factory in mitochon-
dria and the nuclear transcription regulation machinery.
(see figure on previous page)
Fig. 7 Zeb1 overexpression or PTIO administration counteracts AA6 effect in 4T1 cells. a Representative WB (left panel) and relative
densitometry (right panel) of ZEB1, CtBP1, and MMP3 protein levels in 4T1 cells transfected with pCMV6_Zeb1 (grey bars) after 48 h compared to
control vector (pCMV6; black bars). GAPDH was used as a loading control; n= 4. b Representative phase contrast images (left panel) depicting
4T1 cells motility and relative percentage of closure measurements (right panel) after Zeb1 overexpression (pCMV6_Zeb1; dark grey bar and
pCMV6_Zeb1+ AA6–50 µM; medium grey bar) compared to control vector (pCMV6; black bar and pCMV6+ AA6–50 µM; light grey bars). Scale bar
100 μm; n= 4. c Cluster 1 (miR-200b, miR-200a, and miR-429; left panel) and cluster 2 (miR-200c and miR-141; right panel) expression in 4T1 cells after
16 h of treatment with vehicle only (black bars), AA6 (50 µM; light grey bars), AA6 (50 µM)+ PTIO (100 µM; medium grey bars) and PTIO alone
(100 µM; dark grey bars); n= 3. d Representative WB (left panel) and relative densitometry (right panel) of ZEB1 levels in 4T1 cells after 16 h of
treatment with vehicle alone (black bar), AA6 (50 µM; light grey bar), AA6 (50 µM)+ PTIO (100 µM; medium grey bar) and PTIO alone (100 µM; dark
grey bar). GAPDH was used as a loading control; n= 4. e Representative phase contrast images (left panel) depicting 4T1 cells motility and relative
percentage of closure measurements (right panel) in 4T1 cells after 16 h of treatment with vehicle only (black bar), AA6 (50 µM; light grey bar), AA6
(50 µM)+ PTIO (100 µM; medium grey bar) and PTIO alone (100 µM; dark grey bar); n= 4. f Representative WB (left panel) and relative densitometry
(right panel) of ZEB1 levels in 4T1 cells after CRISPR/Cas9 inactivation of KGDH (LCv2_KGDH_1 and LCv2_KGDH_2; light grey bars) compared to
control vector (LCv2_NTC; black bar) with or without PTIO (100 µM; dark grey bars) treatment. GAPDH was used as a loading control; n= 4. Data are
presented as mean ± SE; *p < 0.05, **p < 0.005, ***p < 0.0005 vs controls. Data were analysed by one and two-way ANOVA and non-parametric two-
tailed paired Student’s t-test
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Of interest, our pharmacological approach maintained a
residual KGDH activity, possibly important for cellular
viability. In fact, it has been clearly established that defects
in TCA cycle enzymes, in most of cases, were lethal.
Specifically, during early development, KGDH complex
knock-out is deleterious determining embryonic lethality
in mice60,61, profound growth defects in cancer cell lines
in vitro and in vivo after xenotransplantation62, and α-KG
aciduria in human patients with severely decreased levels
of KGDH activity63. Interestingly, the paucity of patients
with KGDH deficiency further support the relevance of
this specific enzymatic function63. Moreover, these
reports pointed out that only KGDH heterozygosity per-
mits normal embryonal development in consequence of
residual KGDH activity. Our experimental evidence about
KGDH CRISPR/Cas9 cells indeed confirmed that residual
KGDH activity is essential for cell viability. For this rea-
son, single clone selection to obtain monoclonal KGDH
CRISPR/Cas9 cells was unsuccessful, prompting us to
perform experiments in early non-clonal populations
obtained after one round of puromycin selection. Hence,
we hypothesise that the partial KGDH inhibition could be
relevant to the ultimate anticancer effect. The partial
KGDH inhibition, in fact, although preserving cellular
viability, seemed sufficient to reduce their migration/
invasion. Consequently, the anti-metastatic miR-200
family expression was enhanced leading to Zeb1 and
CtBP1 expression inhibition.
The present results suggest that KGDH inhibition and
the reduction of EMT process are associated with a rapid
increase in α-KG. In fact, as depicted in our model (Suppl.
Fig. 8), α-KG availability stabilizes TET expression and
induces miR-200 promoter demethylation paralleled by
an increase of endogenous NO production, fostering their
transcription. Interestingly, NO exerts a contradictory
effect on metastasis development depending on the pri-
mary tumour and the organ target of metastasization50.
While in some cases NO seems to enhance tumour pro-
gression and metastasization64, it also hinders aggres-
siveness of breast cancer65 inhibiting cell migration by
MMP down-modulation66, and lung metastasis reduc-
tion67. In our context the administration of the epi-
metabolic drug AA6, acting on distinct intracellular
pathways, counteracted migration, invasion and metas-
tasis development of 4T1 cells.
In conclusion, we provide here compelling evidences
supporting AA6 as a promising drug to hinder cancer
progression. KGDH targeting led to α-KG increase, able
to activate both TET-dependent DNA demethylation and
NO production, two molecular/metabolic pathways that
might cooperate to hamper the EMT process (Suppl.
Fig. 8). Mechanistically AA6, indirectly targeting miR-200
family-Zeb1/CtBP1 axis, decreased Mmp3 expression
impairing 4T1 invasion ability in vitro and in vivo. In this
view, AA6 might represent a novel epi-metabolically
active small molecule useful in the treatment of experi-
mental metastatic breast cancer.
Materials and methods
Animal model and treatment
8-week-old female BALB/c mice were purchased from
Charles River. To generate spontaneous breast cancer and
relative lung metastasis, 106 murine breast cancer
4T1 cells (ATCC® CRL-2539™) were injected into
the mammary fat pad in mice under the anaesthesia
with isoflurane 2.5%. In all experiments, 4T1 cells
were inoculated at day 0. The mice were divided in groups
at day 7. The dose and the treatment schedule of (S)-2-
[(2,6-dichlorobenzoyl)amino]succinic acid (AA6) were
designed as follows: mice received either 50mg/kg of AA6
(dissolved in PBS, 0.9% p/v NaCl) three times a week or
12.5 mg/kg of AA6 daily, i.p. injections, and were sacri-
ficed after 21 days of treatment (control n= 10, 12.5mg/kg
AA6 n= 10, 50 mg/kg AA6 n= 5). The primary mam-
mary tumours were dissected and measured by digital
caliper. The tumour burden in lung was determined by
hematoxylin and eosin staining. All animal procedures
were approved by the Ethics Committee of the University
of Torino, and by the Italian Ministry of Health, in
compliance with national and international laws (D.Lgs
26/2014 and Directive 2010/63/EU respectively).
Cell culture, treatment and transfection
The murine breast cancer 4T1 cells were purchased
from ATCC (ATCC® CRL-2539™). Cells were cultured in
complete RPMI1640 medium (Gibco) supplemented with
1% L-Glutamine (SIGMA), 1% Penicillin-Streptomycin
(SIGMA) and 10% Foetal Bovine Serum (FBS, MILLI-
PORE). A dose-response curve with the compound AA6
was performed and 50 µM was adopted for further bio-
logical evaluations. For the present study, we verified
AA6 solubility in water ( > 10mg/mL) and its stability in
cell medium. All subsequent studies were performed
using mother solution of AA6 dissolved in water oppor-
tunely diluted in cell medium. 4T1 cells were transfected
with 1 μg of pCMV6_Zeb1 (OriGene) or empty vector
using Lipofectamine 3000 (Invitrogen) according to
manufacturer’s instruction. After 48 h, 4T1 cells were
collected and used for further analyses. Human umbilical
vein endothelial cells (HUVEC) were isolated from human
umbilical veins by trypsin treatment (1%) and cultured in
M199 medium (SIGMA) with the addition of 20% foetal
calf serum (FCS; Gibco), 100 U/mL penicillin (Gibco),
100 μg/mL streptomycin (Gibco), 5 UI/mL heparin,
12 μg/mL bovine brain extract and 200mM glutamine
(Gibco). HUVEC were grown to confluence in flasks and
used from the second to the fifth passage. The use of
HUVEC was approved by the Ethics Committee of the
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“Presidio Ospedaliero Martini” of Turin and conducted in
accordance with the Declaration of Helsinki. Written
informed consent was obtained from all donors. MS-1
from mouse endothelial cells, MDA-MB-231 and
CRL2335 cell lines from human breast carcinoma were
purchased from ATCC® and cultured in DMEM medium
supplemented with 1% L-Glutamine, 1% Penicillin-
Streptomycin and 10% FCS.
Cell motility assay
In the Boyden chamber (BD Biosciences) invasion assay,
cells (2 × 103) were plated onto the apical side of 50 µg/mL
Matrigel-coated filters (8.2mm diameter and 0.5 µm pore
size; Neuro Probe, Inc.) in serum-free medium with or
without increasing concentration of the drugs (0.1–50 μM).
Medium containing 20% FCS was placed in the baso-lateral
chamber as chemo attractant. After 18 h, cells on the apical
side were wiped off with Q-tips. Cells on the bottom of the
filter were stained with crystal-violet and counted with an
inverted microscope. Data are shown as percentages of
migration of treated cells versus the migration measured
for vehicle (water) treated cells. Control migration was 72
± 5 cells (n= 5) using MDA-MB-231, 78 ± 6 using
CRL2335, and 85 ± 7 for 4T1 (mean ± SE).
In vitro scratch assay
4T1 cells, KGDH-CRISPR/Cas9 inactivated-4T1 cells
and Zeb1-overexpressing 4T1 cells were seeded into 12-
well plates and grown to confluence overnight. The cell
monolayer was scratched and covered with RPMI1640
medium (Gibco) supplemented with 1% L-Glutamine
(SIGMA), 1% Penicillin-Streptomycin (SIGMA), 1% Foe-
tal Bovine Serum (FBS, MILLIPORE) and according to the
purpose of experiment treated with or without the drug of
interest (AA6: 10, 25 and 50 µM; PTIO: 100 µM). Images
were captured after 24 h using a Motic AE2000 light
microscope using 10x original magnification (Motic
Electric Group Co. Co.). Areas were measured using
ImageJ imaging software (BioVoxxel Fiji). For each con-
dition mean was calculated and compared to the area at
the starting time point of the experiment.
Cell adhesion assay
HUVEC or MS-1 were grown to confluence in 24-well
plates. Cells were pre-treated or not with increasing
concentrations of AA6 (0.1–50 μM) for 1 h, then were co-
incubated with human or mouse TNF-α (10 ng/mL) for
18 h and washed twice with fresh medium. Tumour cells
(7 × 104 cells/well) were seeded and left to adhere with
HUVEC for 1 h. Unattached tumour cells were washed
away and the number of adherent cells was evaluated by
the Image Pro Plus Software for micro-imaging (Media
Cybernetics, version 5.0, Bethesda). Data are shown as
percentages of adhesion of AA6-treated cells versus the
control adhesion measured on untreated cells; for
HUVEC, the control adhesion per microscope field
(n= 5) was 19 ± 3 using MDA-MB-231, 17 ± 3 using
CRL2335; for MS-1, the control adhesion per microscope
field (n= 12) was 23 ± 4 using 4T1. The TNF-α stimu-
lated adhesion was 193 ± 11% using MDA-MB-231, 231 ±
25 using CRL2335, and 184 ± 14 using 4T1 (mean ± SE).
Transwell cell invasion assay
The invasiveness of 4T1 cells was measured with a
polycarbonate 8-μm porous Transwell membrane (BD
Falcon). The top side of the membrane was incubated 1 h
at 37° C with 1mg/mL Matrigel (BD Biosciences) in PBS.
4T1 cells were harvested and re-suspended in RPMI
serum free medium at the concentration of 7 × 106 cells/mL.
Lower wells of the chamber were loaded with 500 μL
RPMI, 2% FBS. Upper wells were loaded with 100 μL cells
alone or in the presence of AA6 10, 25 and 50 μM. After
incubation for 24 h at 37° C, the top side of the insert
membrane was scrubbed free of cells, and the bottom side
was fixed with 2.5% glutaraldehyde and stained with 0.1%
crystal violet for 15 min, respectively. The images of the
invasive cells in the bottom side of the membrane were
taken under an Olympus BX60F-3 microscope using a
2.5x original magnification.
Breast cancer cell viability assay
Cells (2 × 103/well) were seeded in 96-well plates and,
after 24 h, treated with different concentrations of AA6
(0.1–50 μM) in complete medium. After 72 h of incuba-
tion, viable cells were evaluated by 3-(4,5-Dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide, MTT,
Methylthiazolyldiphenyl-tetrazolium bromide (MTT,
SIGMA) inner salt reagent at 570 nm, as described by the
manufacturer’s protocol. The readings from treated cells
were expressed as percentage versus control measured on
untreated cells.
Colony-forming assay
Cells (1 × 103/well) were seeded into 6-well plates
(well diameter: 34.58 mm) and treated with different
concentrations of AA6 (0.1–50 μM) in complete med-
ium. The medium was changed after 72 h and cells were
cultured for additional 10 days. Subsequently cells were
fixed and stained with a solution of 80% crystal violet
and 20% of ethanol. Colonies were then photographed.
To induce a completely dissolution of the crystal violet
30% acetic acid was added. Absorbance was detected at
595 nm.
miR200c-LNA transfection
4T1 cells were transfected with 50 µM Mircury
scramble or miR-200c LNA-oligonucleotides (Exiqon)
using jetPRIME-siRNA Transfection reagent (Polyplus)
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according to manufacturer’s instructions. After 16 h, cells
were incubated with fresh medium for 32 h and then
treated with AA6 or water, as control, for additional 24 h.
KGDH CRISPR/Cas9 inactivation
To inactivate mouse KGDH, sgRNAs were cloned into
LentiCRISPR2 vector (Addgene) using the GoldenGate
protocol:68
- KGDH_1: Fw 5′-caccgCAGCATCCAAAATCCCCA
G-3′;
Rv 5′-aaacCTGGGGATTTTGGATGCTGc-3′;
- KGDH_2: Fw 5′-caccgGTGAACTGCATGATCCCA
G-3′;
Rv 5′-aaacCTGGGATCATGCAGTTCACc-3′;
Specific CRISPR/Cas9 transfection was compared to a
non-targeting control (NTC) sgRNA:
- NTC: Fw 5′-caccgTTCCGGGCTAACAAGTCCT-3′;
Rv 5′-aaacAGGACTTGTTAGCCCGGAAc-3′.
The obtained plasmids were transformed into NEB 5-
alpha Competent E. coli (High Efficiency –New England
Biolabs), then DNA was purified by EZNA Fastfilter
Endo-Free Plasmid DNA Maxi Kit (Omega Bio-Tek), and
a concentration of 6 μg was used for transfection in
4T1 cells; the transfection was performed using Lipo-
fectamine 3000 (Invitrogen) according to the manu-
facturer’s protocol. All experiments were performed by
using the polyclonal population emerging after a round of
puromycin selection showing residual KGDH expression,
specifically, after 48 h 4T1 cells were selected by 1.5 μg/
mL puromycin recovered from selection and tested for
KGDH knock-out by western blot.
Enzymatic activity assay and metabolite quantification
KGDH Activity Assay Colorimetric Kit (K678, BioVi-
sion), TET Activity/Inhibition Assay Colorimetric Kit
(P3086, Epigentek), the α-KG Assay Colorimetric/
Fluorometric Kit (K677, BioVision), and Arginine quan-
tification kit (CEB938Ge, Cloud-Clone Corp.) were per-
formed according to manufacturer’s instructions. Signals
were detected by EnSpire Multimode Plate Reader (Perkin
Elmer).
Nitric oxide quantification
Nitrate/Nitrite Colorimetric Assay Kit (780001, Cayman
Chemical) was performed according to manufacturer’s
instructions. AA6-treated/untreated 4T1-injected mice
tumorigenic tissue samples (25mg) were lysed in RIPA
buffer (Tris HCl pH 7.4 10mM, NaCl 150mM, NP-40 1%,
sodium deoxycholate (DOC) 1%, SDS 0.1%, glycerol 0.1%,
Protease Inhibitors Cocktail), homogenized and cen-
trifuged, 200 µg of freshly lysed sample were used per
condition. The NO-final products NO3
−+NO2
− were
colorimetrically detected by EnSpire Multimode Plate
Reader (Perkin Elmer). In vitro NO production was
evaluated by adding 4,5-diaminofluorescein diacetate
(DAF-2DA, Cayman Chemical) according to manu-
facturer’s instructions to 4T1 cultured 3, 6, 16, 24 h with
50 µM AA6 or vehicle alone, to 4T1 cells after 16 h of
treatment with vehicle only (water), AA6 (50 µM) and AA6
(50 µM)+ PTIO (SIGMA, 100 µM) and to 4T1 cells after
CRISPR/Cas9 inactivation of KGDH± PTIO (100 µM). At
the end of treatment, cells were collected and analyzed by
FACS (FACS Canto II-BD) to detect intracellular NO
production.
5-methylcytosine and 5-hydroxymethylcytosine global
level quantification
Genomic DNA extraction from AA6-treated/untreated
4T1-injected mice tumorigenic tissue (25 mg) and AA6-
treated/untreated 4T1 cells was performed using the
E.Z.N.A. Tissue DNA kit (D3396, Omega Bio-Tek). 5mC
and 5hmC global levels were evaluated using the ELISA-
based MethylFlash Methylated DNA Quantification Col-
orimetric Kit (P1034, Epigentek) and the MethylFlash
Hydroxymethylated DNA Quantification Colorimetric Kit
(P1036, Epigentek) respectively. The optical density (OD)
was detected by EnSpire Multimode Plate Reader (Perkin
Elmer).
Detection of 5mC on miR-200 family promoter
The 5mC enrichment on miR-200 family promoter was
analyzed by EpimarK 5mC and 5hmC Analysis Kit (New
England Biolabs) according to manufacturer’s instruc-
tions. Briefly, DNA was isolated from AA6-treated/
untreated 4T1-injected mice tumorigenic tissue (25mg)
using the E.Z.N.A. Tissue DNA kit (D3396, Omega Bio-
Tek). The amplified regions were selected on the bases of
CCpGG sites reported on MethPrimer 2.
The following primers were used:
Cluster1 r1 F: 5′- TTTCTATCACAGACACAATACA
G -3′
Cluster1 r1 R: 5′- GAAGTATATCTGACGGGTGT -3′
Cluster1 r2 F: 5′- GGTAGCCTGAGTGTAGACAAG
ACA -3′
Cluster1 r2 R: 5′- CTCTGCAGCAAGCACCCTCC-3′
Cluster2 r1 F: 5′- AAGGAGGAAGAGCGAGAGTG -3′
Cluster2 r1 R: 5′- CCATTTACTGCGTTCTACCGT -3′
Cluster2 r2 F: 5′- TGTTTGGGTGCTGGTTGGGA -3′
Cluster2 r2 R: 5′- CCACCCTTAACTCGGAAGAAG -3′
RNA Extraction, RT-PCR and miRNA Analysis
Total RNA was isolated either from samples deriving
from AA6-treated/untreated 4T1 cells or from AA6-
treated/untreated 4T1-injected mice tumorigenic tissue
(10–25mg) using Tri-Reagent (SIGMA) according to the
instructions of the manufacturer. cDNA synthesis for
quantitative real-time PCR (qRT-PCR) was carried out
with qScript cDNA SuperMix (95048, Quanta
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BIOSCIENCES) following the manufacturer’s protocol.
All reactions were performed in 96-well format in the
StepOne Plus Real-Time PCR System (Applied Biosys-
tems) using PerfeCTa SYBRGreen FastMix, ROX (Quanta
BIOSCIENCES). Each RNA sample was tested in dupli-
cate and P0 was used as housekeeping gene. The Applied
Biosystem software’s Comparative Ct Method (Applied
Biosystem) was used to calculate mRNA expression levels,
data were presented as fold change of transcripts for
target genes. Fold change below 1 shows downregulated
expression versus controls. Primer sequences used for
mRNA analysis were selected based on published
sequence data from NCBI database and listed below:
Gene Species Forward (5′–3′) Reverse (5′–3′)
ZEB1 Mus
Musculus
AGACCAGACAGTATTACCAG CAGAAATTCTTCCACATT
MMP3 Mus
Musculus
ACATGGAGACTTTGTCCCTTTTG TTGGCTGAGTGGTAGAGTCCC
GPNMB Mus
Musculus
AGAAATGGAGCTTTGTCTACGTC CTTCGAGATGGGAATGTATGCC
CtBP1 Mus
Musculus
CAAGAAGGAAGTCAGCCCAG GCCTCAATGAGCACAACCAC
PLAUR Mus
Musculus
CAGAGCTTTCCACCGAATGG GTCCCCGGCAGTTGATGAG
SRC Mus
Musculus
GCTAGAGGCTGGTGTTGATTG GAGTCTGCTGGACTTTCTC
TET1 Mus
Musculus
GAAGGAACAGGAAGCTGCAC CTGGCCAAACCTAGTCTCCA
TET2 Mus
Musculus
GATCCAGGAGGAGCAGTGAG TGGGAGAAGGTGGTGCTATC
TET3 Mus
Musculus
CCGGATTGAGAAGGTCATCTAC AAGATAACAATCACGGCGTTCT
P0 Mus
Musculus
GCGTCCTGGCATTGTCTGT GAAGGCCTTGACCTTTTCAGTAAG
Primers for miR-16, miR-141, miR-200a, miR-200b, miR-
200c, miR-429, primiR-200 cluster1, primiR-200 cluster2
and the reagents for reverse transcriptase and qPCR reac-
tions were all obtained from Applied Biosystems. Relative
expression was calculated using the comparative cycle
threshold (Ct) method (ΔΔCt). miRNA expression levels in
each sample were normalised to miR-16 expression as,
under the experimental conditions of the present study,
miR-16 was not modulated by AA6 treatment.
Metastasis RT2 profiler PCR array
RNA was extracted from AA6-treated/untreated 4T1-
injected mice tumorigenic tissue (10–25mg) using Tri-
Reagent (SIGMA) according to supplier’s instructions.
Briefly, total mRNA was treated with column DNase
treatment (QIAGEN RNeasy mini kit) and converted to
cDNA (RT2 First Standard Kit, 330401, QIAGEN). cDNA
samples were mixed with the ready-to-use RT2 SYBR
Green ROX qPCR master mix (330522, QIAGEN), and
equal volumes were aliquoted to each well of the same
plate (RT2 Profiler PAMM028ZC, QIAGEN) to perform
the real-time PCR cycling programme.
Western blotting
Western blot analyses were performed according to
standard procedures. AA6-treated/untreated 4T1-injected
mice tumorigenic tissue (10–25mg) and AA6-treated/
untreated 4T1 cells samples were lysed in Laemmli buffer
(Tris HCl 100mMpH 6.8, SDS 4%, glycerol 20%, DTT
25mM, NuPAGE LDS Sample Buffer 1x - Invitrogen).
Nitrocellulose blotting membranes were probed with the
following antibodies: ZEB-1 (Santa Cruz), CtBP-1 (Cell
Signaling), GPNMB (Thermo Fisher Sc.), MMP-3 (BIOSS),
SRC (Cell Signaling), KGDH (alias OGDH, Genetex),
TET-1 (Genetex), TET-2 (Santa Cruz) and TET-3 (Novus
Biologicals) flag (SIGMA), α-tubulin (Cell Signaling),
GAPDH (abcam), Grb2 (Santa Cruz). Signals were detec-
ted by Odyssey CLx Infrared Imaging System (LI-COR
Biosciences). Optical density values of specific proteins
were normalized to that of tubulin and corrected for those
obtained from controls that were considered equal to 1.
Subcellular fractionation
5 × 106 AA6-treated/untreated 4T1 cells were lysed with
the lysis buffer provided by Qproteome Cell Compart-
ment kit (QIAGEN), then fractionation was performed
according to the manufacturer’s instructions. Subcellular
fraction content was normalised according to Comassie
staining before western blotting.
Immunofluorescence and confocal microscopy
Confocal analysis was performed according to standard
procedures in AA6-treated/untreated 4T1 cells fixed with
4% paraformaldehyde. TET-1 (1:150, monoclonal, Gene-
tex), TET-2 (1:100, polyclonal, Santa Cruz) and TET-3
(1:150, polyclonal, Novus Biologicals) antibodies were used.
Samples were analysed using a Leica TCS SP8 confocal
microscope using a 40x original magnification. Confocal
analysis of primary tumours was performed to standard
procedures in AA6-treated/untreated primary tumours
using Ki67 (1:400, monoclonal, ThermoFisher Scientific),
Cleaved Caspase-3 (1:50, monoclonal, Cell Signaling) anti-
bodies. Immunofluorescence images were captured by uti-
lising a Leica TCS SPE confocal laser-scanning microscope
using a 20x original magnification (Leica Microsystems) and
by maintaining the same laser power, gain and offset set-
tings. All immune-localisation experiments were performed
on multiple tissue sections.
Immunohistrochemistry
Immunihostochemistry was performed with enzymatic
induced epitope retrieval procedures in AA6-treated/
untreated lungs, using Ki67 (1:200, monoclonal Ther-
moFisher Scientific) and Cleaved Caspase-3 (1:50,
monoclonal, Cell Signaling). The images were taken under
an Olympus BX60F-3 microscope using a 20x and a 40x
original magnification.
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Statistical analysis
Non parametric student’s t-test was used to analyse
variables. Significance between experimental groups was
determined by one or two-way ANOVA followed by the
Bonferroni’s multiple comparison post tests using
GraphPad InStat software. For tumour volume and lung
metastasis we applied non-parametric Mann Withney test
while for the incidence of lung metastasis we applied
Mantel-Cox Test. Overall values of p ≤ 0.05 were deemed
statistically significant. Data indicate the mean values of at
least three independent experiments ± SE. A specific
comment has been added for each analysis.
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